Literature DB >> 25573536

How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.

H Hammarström1, N Kondori, V Friman, C Wennerås.   

Abstract

Detection of the fungal cell wall component beta-glucan (BG) in serum is increasingly used to diagnose invasive fungal infections (IFI), but its optimal use in hematology patients with high risk of IFI is not well defined. We retrospectively analyzed the diagnostic accuracy, optimal cut-off level, and potential confounding factors of BG reactivity. The inclusion criteria were: adult patients with hematologic disease who were admitted to the hematology ward during the 2-year study period and who had two or more consecutive BG assays performed. In total, 127 patients were enrolled. Thirteen patients with proven or probable IFI, as defined by the 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria, were identified. Receiver operating characteristic (ROC) curve analysis showed a high overall diagnostic performance (area under the ROC curve = 0.98) and suggested an optimal cut-off level of 158 pg/ml, with a sensitivity and a specificity of 92 % and 96 %, respectively. Multiway analysis of variance indicated that treatment with pegylated asparaginase (p < 0.001), admission to the intensive care unit (ICU; p = 0.0007), and treatment with albumin, plasma, or coagulation factors (p = 0.01) are potential confounding factors of BG reactivity. We propose that a higher cut-off level than that recommended by the manufacturer should be used to monitor adult hematology patients at high risk for IFI. Our results also suggest that elevated BG levels in patients treated with pegylated asparaginase, albumin, plasma, or coagulation factors, or those admitted to the ICU should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25573536     DOI: 10.1007/s10096-014-2302-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  49 in total

1.  Low incidence of candidaemia among neutropenic patients treated for haematological diseases.

Authors:  E Chryssanthou; M Kalin; P Engervall; B Petrini; M Björkholm
Journal:  Scand J Infect Dis       Date:  1998

2.  False-positive plasma (1-->3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient.

Authors:  Masahiro Ogawa; Hiroki Hori; Shigeko Niiguchi; Eiichi Azuma; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

3.  What is the clinical significance of positive blood cultures with Aspergillus sp in hematopoietic stem cell transplant recipients? A 23 year experience.

Authors:  E Simoneau; M Kelly; A C Labbe; J Roy; M Laverdière
Journal:  Bone Marrow Transplant       Date:  2005-02       Impact factor: 5.483

4.  Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study.

Authors:  Greet De Vlieger; Katrien Lagrou; Johan Maertens; Eric Verbeken; Wouter Meersseman; Eric Van Wijngaerden
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

5.  Toxicity of E. coli L-asparaginase in man.

Authors:  H F Oettgen; P A Stephenson; M K Schwartz; R D Leeper; L Tallai; C C Tan; B D Clarkson; R B Golbey; I H Krakoff; D A Karnofsky; M L Murphy; J H Burchenal
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

6.  Differences in beta-glucan levels in culture supernatants of a variety of fungi.

Authors:  Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Michael R McGinnis; Luis Ostrosky-Zeichner
Journal:  Med Mycol       Date:  2006-05       Impact factor: 4.076

7.  Release of (1-->3)-beta-D-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production.

Authors:  Atsushi Ohata; Makoto Usami; Takashi Horiuchi; Koichi Nagasawa; Keiko Kinoshita
Journal:  Artif Organs       Date:  2003-08       Impact factor: 3.094

8.  Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease.

Authors:  Sophia Koo; Julie M Bryar; John H Page; Lindsey R Baden; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients.

Authors:  R Y Hachem; D P Kontoyiannis; R F Chemaly; Y Jiang; R Reitzel; I Raad
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

View more
  10 in total

1.  Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

2.  Measuring (1,3)-β-D-glucan in tracheal aspirate, bronchoalveolar lavage fluid, and serum for detection of suspected Candida pneumonia in immunocompromised and critically ill patients: a prospective observational study.

Authors:  Kang-Cheng Su; Kun-Ta Chou; Yi-Han Hsiao; Ching-Min Tseng; Vincent Yi-Fong Su; Yu-Chin Lee; Diahn-Warng Perng; Yu Ru Kou
Journal:  BMC Infect Dis       Date:  2017-04-08       Impact factor: 3.090

Review 3.  Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  Maximilian Christopeit; Martin Schmidt-Hieber; Rosanne Sprute; Oliver A Cornely; Georg Maschmeyer; Dieter Buchheidt; Marcus Hentrich; Meinolf Karthaus; Olaf Penack; Markus Ruhnke; Florian Weissinger
Journal:  Ann Hematol       Date:  2020-10-20       Impact factor: 3.673

Review 4.  Specificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease.

Authors:  Malcolm A Finkelman
Journal:  J Fungi (Basel)       Date:  2020-12-29

5.  Performance characteristics of Fungitell STAT™, a rapid (1→3)-β-D-glucan single patient sample in vitro diagnostic assay.

Authors:  Robert L D'Ordine; Kevin A Garcia; Josee Roy; Yonglong Zhang; Barbara Markley; Malcolm A Finkelman
Journal:  Med Mycol       Date:  2021-01-04       Impact factor: 4.076

6.  Infectious Complications in Paediatric Haematopoetic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status.

Authors:  Olga Zajac-Spychala; Stefanie Kampmeier; Thomas Lehrnbecher; Andreas H Groll
Journal:  Front Pediatr       Date:  2022-02-10       Impact factor: 3.418

Review 7.  Fungal infections diagnosis - Past, present and future.

Authors:  Alexandre Mendonça; Helena Santos; Ricardo Franco-Duarte; Paula Sampaio
Journal:  Res Microbiol       Date:  2021-12-01       Impact factor: 3.946

8.  Evaluation of the Dynamiker® Fungus (1-3)-β-D-Glucan Assay for the Diagnosis of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies.

Authors:  Maria Siopi; Stamatis Karakatsanis; Christoforos Roumpakis; Konstantinos Korantanis; Elina Eldeik; Helen Sambatakou; Nikolaos V Sipsas; Maria Pagoni; Maria Stamouli; Panagiotis Tsirigotis; Joseph Meletiadis
Journal:  Infect Dis Ther       Date:  2022-04-11

9.  (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.

Authors:  Sandra K White; Robert L Schmidt; Brandon S Walker; Kimberly E Hanson
Journal:  Cochrane Database Syst Rev       Date:  2020-07-21

10.  T2Candida Assay in the Diagnosis of Intraabdominal Candidiasis: A Prospective Multicenter Study.

Authors:  Anders Krifors; Måns Ullberg; Markus Castegren; Johan Petersson; Ernesto Sparrelid; Helena Hammarström; Jan Sjölin; Volkan Özenci; Ola Blennow
Journal:  J Fungi (Basel)       Date:  2022-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.